137 related articles for article (PubMed ID: 26801792)
1. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
2. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
[No Abstract] [Full Text] [Related]
3. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
Kobayashi H; Miyagi N
Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
Dittus C; Grover N; Ellsworth S; Tan X; Park SI
Leuk Lymphoma; 2018 Sep; 59(9):2121-2127. PubMed ID: 29303024
[TBL] [Abstract][Full Text] [Related]
5. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Arora N; Gupta A; Sadeghi N
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364
[TBL] [Abstract][Full Text] [Related]
6. Solitary plasmablastic lymphoma in the esophagus.
Mihara K; Sasaki N; Mamoru O; Kanbe M; Ichinohe T; Suehiro S
Ann Hematol; 2016 Apr; 95(5):845-6. PubMed ID: 26925582
[No Abstract] [Full Text] [Related]
7. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Castillo JJ; Reagan JL; Sikov WM; Winer ES
Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
[TBL] [Abstract][Full Text] [Related]
8. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
9. Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
Aurer I; Bašić-Kinda S; Radman I; Ilić I; Grah JJ
Ann Hematol; 2014 Jan; 93(1):177-8. PubMed ID: 23636314
[No Abstract] [Full Text] [Related]
10. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
[TBL] [Abstract][Full Text] [Related]
11. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
[TBL] [Abstract][Full Text] [Related]
12. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
13. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
[TBL] [Abstract][Full Text] [Related]
14. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Castillo JJ; LaMacchia J; Flynn CA; Sarosiek S; Pozdnyakova O; Treon SP
Br J Haematol; 2021 Nov; 195(3):466-468. PubMed ID: 34355802
[No Abstract] [Full Text] [Related]
15. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings.
Yanamandra U; Sahu KK; Jain N; Prakash G; Saikia U; Malhotra P
Ann Hematol; 2016 Oct; 95(10):1715-7. PubMed ID: 27324386
[No Abstract] [Full Text] [Related]
16. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
17. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Fabbri A; Gozzetti A; Rigacci L
Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
[No Abstract] [Full Text] [Related]
18. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.
Dunleavy K; Pittaluga S; Shovlin M; Roschewski M; Lai C; Steinberg SM; Jaffe ES; Wilson WH
Haematologica; 2016 Jan; 101(1):e27-9. PubMed ID: 26518748
[No Abstract] [Full Text] [Related]
19. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690
[No Abstract] [Full Text] [Related]
20. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]